GUILFORD, Conn., March 26, 2019 (GLOBE NEWSWIRE) — InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, was featured in a Microsoft-sponsored AI for Change series that showcases companies making a transformative impact in their industry with AI technology. InveniAI was specifically featured to showcase the transformative impact of AI on pharmaceutical research and development.
Krishnan Nandabalan, Ph.D., President and CEO, InveniAI Corp said, “We are excited to be featured in the Microsoft AI for Change series with our artificial intelligence and machine learning platform, AlphaMeld™. AlphaMeld is our universal value detection system that has transformed the process of identifying and accessing novel innovation. Its AI amplifies our capability to decipher hidden connections that help us discover solutions for unmet needs with unprecedented speed and scale, an increased probability of success, and a significant reduction in the risk of failure.”
“We are at an interesting juncture where we see increasing adoption of AI in sectors such as consumer healthcare, food and nutrition, technology innovations, cybersecurity, animal health, logistics, and manufacturing,” added Aman Kant, Chief Business Officer, InveniAI. “We very quickly realized through our collaborations that the applications of AlphaMeld are not industry-bound but in fact universally applicable to detect the earliest signals of innovation in any industry.”
The Microsoft sponsored report spotlighting InveniAI on NowThis Future can be viewed here.
InveniAI® Corporation, a wholly owned subsidiary and technology spin-out of BioXcel Corporation, has pioneered the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries. The company leverages AI and ML to harness petabytes of disparate data sets to recognize and unlock value for AI-based innovation monitoring and AI-based drug discovery and development. Numerous industry collaborations with Big Pharma, Specialty Pharma, and BioPharma showcase the value of the platform in recognizing complex patterns and associations that complement and amplify human expertise. The company continues to collaborate with industry partners to address cutting-edge problems across the value chain from internal to external innovation and to complement corporate decision making. InveniAI is headquartered in Guilford, CT, USA.
David Schull or Travis Kruse